Immunic exercises exclusive IMU-856 global license option from Daiichi
Category: #health  By Mateen Dalal  Date: 2020-01-10
  • share
  • Twitter
  • Facebook
  • LinkedIn

Immunic exercises exclusive IMU-856 global license option from Daiichi

Immunic, a renowned biopharmaceutical company focused on treating autoimmune and chronic inflammatory diseases, reportedly announced that its subsidiary, Immunic AG, has implemented its exclusive global license option for a group of compounds that are designated by it as IMU-856.

The company exercised this option under the terms of its license agreement and existing option with Japanese pharmaceutical company, Daiichi Sankyo.

The company plans to initiate a phase 1 clinical trial for this novel program during the first half of 2020. The IMU-856 is a small molecule, orally available modulator that aims at a yet undisclosed protein that works like a transcriptional regulator for the intestinal barrier function.

IMU-856 signifies a novel and potentially disruptive method to treat intestinal diseases. the molecule also is capable of restoring the intestinal barrier function and it would also maintain immunocompetency.

President and Chief Executive Officer of Immunic, Daniel Vitt, Ph.D., stated that practicing this option is a vital milestone, as it signifies that the company is convinced about the IMU-856’s preclinical safety profile. Further, the company is ready to move ahead and take the program in phase 1 clinical studies, which it intends to start in the first half of 2020.  

Vitt further added that the company’s recently showcased preclinical information reinforced its belief that IMU-856 has disease-modifying features for several intestinal diseases and shows potential significant benefits on present immunosuppressive therapies which tackles inflammation while unintentionally reducing the immune surveillance of the body.

Vitt also added that the company is hopeful that this phase 1, multiple and single ascending dose trials would serve as a vital step for IMU-856’s development as a safe therapy option for patients with gastrointestinal diseases through restoring intestinal barrier function without impairing the patient’s immune system.

Senior Executive Officer and Global Head of R&D at Daiichi Sankyo, Junichi Koga stated that the company is pleased that Immunic exercised the option for IMU-856. The company is dedicated to providing innovative medicines to patients throughout the world as fast as possible, either by itself or from strategic partnerships.

Koga further added that the company is confident that Immunic is its best partner and would quickly propel the development of this new compound for patients suffering from intestinal diseases.

 

Source credit: https://www.immunic-therapeutics.com/2020/01/08/immunic-exercises-its-option-for-the-exclusive-worldwide-license-to-imu-856-from-daiichi-sankyo-co-ltd/

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

NHS requests urgent donations of blood plasma from COVID-19 survivors
NHS requests urgent donations of blood plasma from COVID-19 survivors
By Mateen Dalal

According to reliable sources, United Kingdom National Health Service (NHS) has filed an appeal to the individuals recuperated from novel coronavirus to donate blood plasma. The organization apparently intends to treat the people who get infected dur...

OSE Immunotherapeutics receives $228,000 to develop COVID-19 vaccine
OSE Immunotherapeutics receives $228,000 to develop COVID-19 vaccine
By Mateen Dalal

The novel coronavirus outbreak has turned out to be one of the worst disasters the world has witnessed in recent times. At times like this, pharmaceutical companies worldwide have been putting their best foot forward to find the vaccine for COVID-19....

Singapore’s ESR and Sabana REIT propose merger amid pandemic
Singapore’s ESR and Sabana REIT propose merger amid pandemic
By Mateen Dalal

Although the economic impact of the ongoing COVID-19 has significantly impacted prospects for Singapores REITs (Real Estate Investment Trusts), it seems that some resilient spots in the real estate sector will remain where they were. In the latest st...